Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Transcode Therapeutics Inc (NQ: RNAZ ) 0.2365 +0.0038 (+1.63%) Streaming Delayed Price Updated: 4:00 PM EDT, Sep 4, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Transcode Therapeutics Inc < Previous 1 2 3 4 5 6 7 8 9 ... 12 13 Next > 12 Health Care Stocks Moving In Monday's Intraday Session May 13, 2024 Via Benzinga Why TransCode Therapeutics (RNAZ) Stock Is Getting Hammered May 13, 2024 TransCode Therapeutics shares are trading lower by 40.6% during Monday's session. The company disclosed plans for a potential reverse stock split in an open letter to its shareholders. Via Benzinga Squarespace (SQSP) Stock Climbs 13% on $6.9 Billion Deal to Go Private May 13, 2024 Squarespace stock is up on Monday as SQSP investors react to a $6.9 billion deal to take the business management company private. Via InvestorPlace Why Is TransCode Therapeutics (RNAZ) Stock Down 14% Today? May 13, 2024 TransCode Therapeutics stock is down on Monday after the company announced plans for a shareholder meeting for RNAZ investors. Via InvestorPlace TransCode Therapeutics Open Letter to Shareholders May 13, 2024 From TransCode Therapeutics, Inc. Via GlobeNewswire Looking Into TransCode Therapeutics's Recent Short Interest January 29, 2024 Via Benzinga 12 Health Care Stocks Moving In Monday's Pre-Market Session May 13, 2024 Via Benzinga Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday May 13, 2024 It's time to start the trading week with a breakdown of the biggest pre-market stock movers worth watching on Monday morning! Via InvestorPlace TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors April 15, 2024 Clinical trial expected to commence in mid-2024 to evaluate the safety and preliminary anti-tumor activity of TTX-MC138 From TransCode Therapeutics, Inc. Via GlobeNewswire TransCode Therapeutics Reports 2023 Results; Provides Business Update April 03, 2024 From TransCode Therapeutics, Inc. Via GlobeNewswire TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer March 28, 2024 Medical oncologist brings over 25 years of industry experience to lead Clinical Development Strategy From TransCode Therapeutics, Inc. Via GlobeNewswire TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment March 11, 2024 From TransCode Therapeutics, Inc. Via GlobeNewswire TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress March 06, 2024 Highlights TTX-MC138’s Path from Target Discovery to the Clinic From TransCode Therapeutics, Inc. Via GlobeNewswire TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode’s RIG-I Agonist Immunotherapeutic February 20, 2024 From TransCode Therapeutics, Inc. Via GlobeNewswire Why Nextracker Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket February 01, 2024 Shares of Nextracker Inc. (NASDAQ: NXT) rose sharply during today’s pre-market trading after the company reported better-than-expected thi Via Benzinga Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday February 01, 2024 It's time to get into the biggest pre-market stock movers as we check out all of the hottest news happening on Thursday morning! Via InvestorPlace 12 Health Care Stocks Moving In Wednesday's After-Market Session January 31, 2024 Via Benzinga Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders’ Equity Requirement and Continued Listing on The Nasdaq Stock Market January 31, 2024 From TransCode Therapeutics, Inc. Via GlobeNewswire TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer January 29, 2024 Project to test combination of TransCode’s proprietary TTX delivery platform and Debiopharm’s drug delivery technologies From TransCode Therapeutics, Inc. Via GlobeNewswire TransCode Therapeutics Announces Closing of $7.25 Million Public Offering January 22, 2024 From TransCode Therapeutics, Inc. Via GlobeNewswire 12 Health Care Stocks Moving In Monday's After-Market Session January 22, 2024 Via Benzinga Why TransCode Therapeutics Shares Are Trading Lower By Over 24%? Here Are Other Stocks Moving In Friday's Mid-Day Session January 19, 2024 Shares of TransCode Therapeutics, Inc. (NASDAQ: RNAZ) fell sharply during Friday’s session. TransCode Therapeutics priced a 5,942,623 share common stock offering at $1.22 per share. TransCode... Via Benzinga 12 Health Care Stocks Moving In Friday's Intraday Session January 19, 2024 Via Benzinga TransCode Therapeutics Announces Pricing of $7.25 Million Public Offering January 18, 2024 From TransCode Therapeutics, Inc. Via GlobeNewswire Why Airspan Networks Shares Are Trading Higher By Over 380%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session January 17, 2024 Shares of Airspan Networks Holdings Inc. (NASDAQ: MIMO) shares rose sharply during Wednesday’s session after the company announced a partnership with GCT Semiconductor to develop an RF module. Airspan... Via Benzinga TransCode Therapeutics Reports Further Restructuring to Reduce Expenses and Increased Focus on Planned Phase 1 Clinical Trial, Retirement of CEO January 12, 2024 From TransCode Therapeutics, Inc. Via GlobeNewswire TransCode Therapeutics Announces 1-for-40 Reverse Stock Split January 11, 2024 From TransCode Therapeutics, Inc. Via GlobeNewswire TransCode Therapeutics Publishes Open Letter Outlining Company’s Progress and Objectives January 04, 2024 Despite Difficult Financial Markets, TransCode Raised New Capital and Initiated Its First Clinical Trial With Its Lead Therapeutic Candidate, A First-in-Class Compound Designed to Treat Metastatic... From TransCode Therapeutics, Inc. Via GlobeNewswire TransCode Therapeutics Reports Positive Pre-Clinical Results in Metastatic Pancreatic Cancer with its Lead Candidate, TTX-MC138 December 12, 2023 TTX-MC138 is Effective in Animal Models of Human Metastatic Pancreatic Cancer From TransCode Therapeutics, Inc. Via GlobeNewswire TransCode Therapeutics To Present Phase 0 Data at 2023 San Antonio Breast Cancer Symposium December 05, 2023 From TransCode Therapeutics, Inc. Via GlobeNewswire < Previous 1 2 3 4 5 6 7 8 9 ... 12 13 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.